GGB Awards Extend Entry Deadline To 26 August
Entry Period Extended By A Week Ahead Of 2 November Ceremony In Frankfurt
Entrants now have an additional week to submit entries for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt this November.
You may also be interested in...
Shreehas Tambe has been named as CEO of Biocon Biologics, taking over from Arun Chandavarkar, in the wake of the company’s milestone $3bn transaction for Viatris’s biosimilars business.
Dan Leonard has announced his resignation as president and CEO of the US Association for Accessible Medicines. He will be replaced on an interim basis by the group’s vice president for sciences and regulatory affairs, David Gaugh.
The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.